MX2009006171A - Metodo para la prevencion o el tratamiento de isquemia de miocardio. - Google Patents

Metodo para la prevencion o el tratamiento de isquemia de miocardio.

Info

Publication number
MX2009006171A
MX2009006171A MX2009006171A MX2009006171A MX2009006171A MX 2009006171 A MX2009006171 A MX 2009006171A MX 2009006171 A MX2009006171 A MX 2009006171A MX 2009006171 A MX2009006171 A MX 2009006171A MX 2009006171 A MX2009006171 A MX 2009006171A
Authority
MX
Mexico
Prior art keywords
treatment
dgat1
preventing
myocardial ischemia
inhibitor compound
Prior art date
Application number
MX2009006171A
Other languages
English (en)
Inventor
Thomas Edward Hughes
Avirup Bose
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009006171A publication Critical patent/MX2009006171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Un método para la prevención o el tratamiento de isquemia de miocardio mediante la inhibición de la enzima DGAT1 con un compuesto inhibidor de DGAT1.
MX2009006171A 2006-12-11 2007-12-10 Metodo para la prevencion o el tratamiento de isquemia de miocardio. MX2009006171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86944806P 2006-12-11 2006-12-11
PCT/US2007/086919 WO2008073865A2 (en) 2006-12-11 2007-12-10 Method of preventing or treating myocardial ischemia

Publications (1)

Publication Number Publication Date
MX2009006171A true MX2009006171A (es) 2009-06-19

Family

ID=39186851

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006171A MX2009006171A (es) 2006-12-11 2007-12-10 Metodo para la prevencion o el tratamiento de isquemia de miocardio.

Country Status (11)

Country Link
US (1) US20100016387A1 (es)
EP (1) EP2101783A2 (es)
JP (1) JP2010512410A (es)
KR (1) KR20090098877A (es)
CN (1) CN101600437A (es)
AU (1) AU2007333234A1 (es)
BR (1) BRPI0720023A2 (es)
CA (1) CA2671315A1 (es)
MX (1) MX2009006171A (es)
RU (1) RU2009126418A (es)
WO (1) WO2008073865A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138304A1 (en) 2006-05-30 2007-12-06 Astrazeneca Ab 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors
ES2535083T3 (es) 2007-12-20 2015-05-05 Astrazeneca Ab Compuestos de carbamoilo como inhibidores 190 de DGAT1
TW201000099A (en) 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
US20110301192A1 (en) * 2008-10-01 2011-12-08 The Regents Of The University Of California Inhibitors of Cyclin Kinase Inhibitor p21
EP2805951B1 (en) 2009-03-20 2018-03-14 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof
WO2010146395A1 (en) 2009-06-19 2010-12-23 Astrazeneca Ab Pyrazine carboxamides as inhibitors of dgat1
JP2013531037A (ja) * 2010-07-13 2013-08-01 メルク・シャープ・エンド・ドーム・コーポレイション スピロ環式化合物
PL2625172T3 (pl) * 2010-10-07 2017-07-31 Novartis Ag Nowe formy krystaliczne soli sodowej kwasu (4-{4-[5-(6-trifluorometylopirydyn-3ylo-amino)-pirydyn-2-ylo]-fenylo}-cykloheksylo)-octowego
CN102988351A (zh) * 2012-11-19 2013-03-27 何晓涛 Aphanamixoid A在制备治疗心肌缺血药物中的应用
JP6252009B2 (ja) * 2013-07-24 2017-12-27 Jnc株式会社 新規ジアミン、これを用いたポリマー、液晶配向剤、液晶配向膜、および液晶表示素子
EP3102576B8 (en) 2014-02-03 2019-06-19 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
PT3207043T (pt) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016133364A1 (ko) * 2015-02-17 2016-08-25 주식회사 엘지화학 봉지 필름
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
AU2018307919B2 (en) 2017-07-24 2022-12-01 Vitae Pharmaceuticals, Llc Inhibitors of RORϒ
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
PL3752501T3 (pl) 2018-02-13 2023-08-21 Gilead Sciences, Inc. Inhibitory pd-1/pd-l1
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3830093A1 (en) 2018-07-27 2021-06-09 Biotheryx, Inc. Bifunctional compounds as cdk modulators
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN115298168A (zh) * 2020-01-28 2022-11-04 普罗泰格生物制药公司 用于稳定甲状腺素运载蛋白和抑制甲状腺素运载蛋白错误折叠的化合物、组合物和方法
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100404358B1 (ko) * 1998-01-28 2003-11-03 시오노기세이야쿠가부시키가이샤 신규 삼환식 화합물
CA2348234A1 (en) * 1998-10-29 2000-05-11 Chunjian Liu Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
CA2507406A1 (en) * 2002-11-05 2004-05-21 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
CN1753897A (zh) * 2002-11-22 2006-03-29 日本烟草产业株式会社 稠合双环含氮杂环
WO2005013907A2 (en) * 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
BRPI0516483A (pt) * 2004-10-15 2008-09-02 Bayer Pharmaceuticals Corp preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
NZ555683A (en) * 2004-12-14 2010-09-30 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
US20090048258A1 (en) * 2005-02-01 2009-02-19 Masaki Ogino Amide Compound
EP1874317A4 (en) * 2005-04-19 2011-10-26 Bayer Healthcare Llc PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES IN THE TREATMENT OF OBESITY
PL2402319T3 (pl) * 2006-03-31 2018-02-28 Novartis Ag Inhibitory DGAT

Also Published As

Publication number Publication date
CN101600437A (zh) 2009-12-09
KR20090098877A (ko) 2009-09-17
CA2671315A1 (en) 2008-06-19
WO2008073865A2 (en) 2008-06-19
JP2010512410A (ja) 2010-04-22
BRPI0720023A2 (pt) 2018-09-04
WO2008073865A3 (en) 2009-02-12
US20100016387A1 (en) 2010-01-21
EP2101783A2 (en) 2009-09-23
RU2009126418A (ru) 2011-01-20
AU2007333234A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
MX2009006171A (es) Metodo para la prevencion o el tratamiento de isquemia de miocardio.
MX2010005395A (es) Metodo para tratar artritis.
MX2009005934A (es) Compuestos organicos.
MX2011011735A (es) Compuestos y metodos para la inhibicion de renina, e indicaciones para ello.
WO2007139992A3 (en) ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
TW200639166A (en) Amino-pyridines as inhibitors of β-secretase
WO2010071846A3 (en) Compounds for treating neuropsychiatric conditions
MX2009006481A (es) Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona.
GEP20135957B (en) Heterocyclic compound and usage thereof
UA97474C2 (ru) Соединения для лечения нарушений, связанных с активностью dgat1
WO2008112199A8 (en) Method for inhibiting topoisomerase ii
MX2012006913A (es) Profarmacos de inhibidores de calicreina plasmatica.
ATE507211T1 (de) Triazin-11-beta-hydroxysteroid-dehydrogenase- artige hemmer
SG171593A1 (en) Inhibitors of c-fms kinase
ZA200900553B (en) Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions
IL186293A0 (en) Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor
MX340304B (es) Antagonismo de smoothened para el tratamiento de los trastornos relacionados con la senda de hedgehog.
MX2010005768A (es) Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral.
TNSN08191A1 (en) Kinase inhibitors
MX2008000703A (es) Composicion sinergica y metodo para inhibir el crecimiento de microorganismos.
TW200732281A (en) Heterocyclic CETP inhibitors
MY150493A (en) Quinazoline derivatives
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
UA105527C2 (uk) Сполука-інгібітор матриптази для лікування раку
MY151937A (en) Water treatment composition

Legal Events

Date Code Title Description
FA Abandonment or withdrawal